Chief Accounting Officer Jonathan Wygant sold 24,000 shares on May 22, 2026, generating a transaction value of ~$1.09 million at an average price around $45.40 per share. This transaction reduced direct holdings by 34.57%, leaving 45,434 shares directly owned post-sale.

VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.

A director of Veracyte reported selling 3,729 shares for a transaction value of approximately $197K on June 18, 2026. This disposition represented roughly 20% of Karin Eastham's direct common stock holdings, reducing direct ownership to 15,097 shares.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

On the heels of the landmark [url="]OPTIMA trial[/url] readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostic

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.